

Review Article

Natural Sesquiterpene Lactones Enhance Chemosensitivity of Tumor Cells through Redox Regulation of STAT3 Signaling

Elena Butturini, Alessandra Carcereri de Prati, Diana Boriero, and Sofia Mariotto 

Department of Neuroscience, Biomedicine and Movement Sciences, Section of Biological Chemistry, University of Verona, Strada Le Grazie, 8, 37134 Verona, Italy

Correspondence should be addressed to Sofia Mariotto; sofia.mariotto@univr.it

Received 16 April 2019; Revised 7 August 2019; Accepted 5 September 2019; Published 28 October 2019

Guest Editor: Adil Mardinoglu

Copyright © 2019 Elena Butturini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

STAT3 is a nuclear transcription factor that regulates genes involved in cell cycle, cell survival, and immune response. Although STAT3 activation drives cells to physiological response, its deregulation is often associated with the development and progression of many solid and hematological tumors as well as with drug resistance. STAT3 is a redox-sensitive protein, and its activation state is related to intracellular GSH levels. Under oxidative conditions, STAT3 activity is regulated by S-glutathionylation, a reversible posttranslational modification of cysteine residues. Compounds able to suppress STAT3 activation and, on the other hand, to modulate intracellular redox homeostasis may potentially improve cancer treatment outcome. Nowadays, about 35% of commercial drugs are natural compounds that derive from plant extracts used in phytotherapy and traditional medicine. Sesquiterpene lactones are an interesting chemical group of plant-derived compounds often employed in traditional medicine against inflammation and cancer. This review focuses on sesquiterpene lactones able to downmodulate STAT3 signaling leading to an antitumor effect and correlates the anti-STAT3 activity with their ability to decrease GSH levels in cancer cells. These properties make them lead compounds for the development of a new therapeutic strategy for cancer treatment.

1. Introduction

Cancer is the main single cause of death in both men and women, claiming over 6 million lives each year worldwide. The hallmarks of cancer include tumor cell proliferation and survival, tumor angiogenesis, and metastasis. Tumor cells exhibit an altered metabolism that allows them to sustain high proliferative rates and resist to some cell death signals, particularly those mediated by increased oxidative stress. Several studies have identified a critical role of aberrant activation of STAT3 signaling in oncogenesis. Therefore, any treatment counteracting the STAT3 hyperactivation has been considered as a new strategy to treat different tumors.

Over the last 20 years, a lot of literature evidence indicates that many derived plant substances are potentially interesting in cancer therapy or can be considered as lead compounds to develop new possible anticancer drugs.

2. Signal Transducer and Activator of Transcription 3

2.1. STAT3 Structure. Signal transducer and activator of transcription 3 (STAT3) is a member of a family of seven proteins (STAT 1, 2, 3, 4, 5a, 5b, and 6) activated by growth factors and cytokines that participate in physiological cellular responses [1, 2]. The transcript of STAT3 undergoes alternative splicing, resulting in the full length STAT3 α (92 kDa) and in the truncated isoform STAT3 β (83 kDa) that lacks the C-terminal domain including Ser727 [3].

Two crystal structures of STAT3 are deposited in the Protein Data Bank (PDB): the phosphorylated STAT3 β -DNA complex (1BG1) [4] and the unphosphorylated STAT3 core fragment (3CWG) [5]. Sequence comparisons, biochemical assays, and mutagenesis have identified six functional conserved domains within the STAT3 molecule, each of them contributing to various aspects of signal transduction




FIGURE 1: STAT3 signaling pathway. p-STAT3: phosphorylated STAT3; p-JAKs: phosphorylated JAKs; SOCS: suppressor of cytokine signaling proteins; PIAS: protein inhibitors of activated STATs; PTPs: protein tyrosine phosphatases.

pathway. The domains are arranged in the protein structure as follows: an N-terminal domain (NTD) (1-137), a coiled-coil domain (CCD) (138-320) formed by a four-helix bundle, a DNA-binding domain (DBD) (321-494) comprising an eight-stranded β -barrel, a α -helical linker domain (LD) (495-583), a Src homology 2 (SH2) domain (584-688), and a C-terminal transcriptional activation domain (TAD) (723-770). The NTD is a conserved sequence that mediates tetramerization of two phosphorylated dimers which cooperatively bind specific STAT3 sites in a gene promoter [6, 7]. The CCD is critical for recruitment of STAT3 to the receptor, subsequent phosphorylation and dimerization, and its translocation into the nucleus [8]. Moreover, the CCD is involved in protein-protein interactions leading to multiple types of dimer complexes, and it also contains a lysine residue (Lys140) subject to methylation by histone methyl transferase SET9, which is a negative regulatory event [9]. The DBD allows the recognition and the binding to a specific consensus sequence defining the DNA-binding specificity. The SH2 domain is required for the recruitment of signal transduction proteins to activated receptors and contains a key binding pocket where the phosphotyrosine residue of other STAT proteins can bind to form homo- or heterodimers [10]. Other than SH2 domain interaction, we have recently detected two interchain disulfides between cysteine 367 and cysteine 542 and between cysteine 418 and cysteine 426 (Cys367-Cys542 and Cys418-Cys426) responsible for STAT3 dimer stabilization [11]. Finally, the TAD is involved in transcriptional activation and promotes the full STAT3 activation through the phosphorylation of the serine residue 727 (Ser727). In

the C-terminal domain, between SH2 and TAD, there is a tail segment with the phosphorylation site tyrosine 705 (Tyr705) that controls dimerization and yields the DNA-binding activity of STAT3 [12].

2.2. STAT3 Signaling Cascade. Multiple distinct steps are involved within the STAT3 signaling pathway. According to the classical model, STAT3 is activated through the binding of growth factors and cytokines to their cell-surface receptors. Cytokines, like IL-6, IL-10, and IL-11, as well as growth factors, like endothelial growth factor (EGF), vascular endothelial growth factor (VEGF), and fibroblast growth factor (FGF), can activate the phosphorylation cascade. This event allows rapid transphosphorylation and activation of Janus tyrosine kinases (JAKs, JAK1, JAK2, JAK3, and Tyk2) that phosphorylate tyrosine residues on the cytoplasmic tail of the receptors. The SH2 domain of STAT3 recognizes and binds to these docking sites, placing STAT3 within close proximity of active JAKs, which subsequently phosphorylate STAT3 at Tyr705. The phosphorylated form of STAT3 homo- or heterodimerizes via reciprocal SH2 domain interaction and translocates from the cytoplasm to the nucleus, where it regulates the transcription of target genes (Figure 1) [13, 14]. In addition to JAKs, STAT3 can be activated by nonreceptor tyrosine kinases such as Src and ABL [15–17]. Furthermore, various serine kinases, like protein kinase C (PKC), mitogen-activated protein kinases (MAPK), and CDK5, phosphorylate the OH residue of Ser727. Although serine phosphorylation occurs in several cells, its biologic role is still controversial. Some authors report that

TABLE 1: STAT3-regulated genes.

Tumor-supporting functions of STAT3		
Biological functions	Genes	References
Apoptosis	Bcl-2	↑ [44]
	Mcl-1	↑ [24, 30]
	Bcl-xL	↑ [25, 30]
	Survivin	↑ [26, 30]
	Skp2	↑ [27]
	Fas	↓ [28]
Proliferation	c-Myc	↑ [30]
	Pim-1	↑ [30]
	Cyclin-D1	↑ [23]
Angiogenesis	VEGF	↑ [29, 31]
	bFGF	↑ [32]
Immune suppression	IL-10	↑ [33]
	IL-12	↓ [34]
Invasion and metastasis	MMP-1	↑ [30, 36]
	MMP-2	↑ [30, 35]
	MMP-3	↑ [36]
	MMP-9	↑ [36, 37]
	Vimentin	↑ [38]
	TWIST-1	↑ [39]
	p53	↓ [45]
Cancer stem cell	CPT1B	↑ [40]
Self-renewal	ALDH1A1	↑ [41]
Chemoresistance	SOX2	↑ [42]

serine phosphorylation allows to achieve maximal transcriptional activity [18], whereas others demonstrate that serine phosphorylation inhibits STAT3 activity [19, 20].

The binding of STAT3 to a specific DNA domain promotes the expression of numerous genes involved in cell cycle progression, apoptosis, tumor angiogenesis, invasion, metastasis, chemoresistance, immunosuppression, and cancer stem cell renewal (Table 1) [21–40]. Intriguingly, many downstream target genes of STAT3 encode cytokines and growth factors that trigger the same STAT3 signaling pathway, thereby providing a mechanism of autocrine and paracrine STAT3 activation.

Under physiological conditions, the activation of STAT3 signaling is a transient and tightly regulated process that can last from half an hour to several hours. After this period, the signal decays and STAT3 are exported back to the cytoplasm. This decay entails downregulation of both receptors and JAKs, as well as of STAT3 transcriptional activity, and involves several negative protein modulators, including the family of suppressor of cytokine signaling proteins (SOCS), the protein inhibitors of activated STATs (PIAS), and several protein tyrosine phosphatases (PTPs) [41, 42] (Figure 1).

The SOCS family is composed by eight inducible intracellular proteins, all characterized by the SH2 domain that interacts with phosphorylated JAKs and/or with the intracellular domains of the receptors to impede the recruitment of STATs

to the docking sites as well as to inhibit JAK activity. Moreover, via their SOCS box domain, SOCS interact with E3 ubiquitin ligase and promote the ubiquitin-dependent degradation of targets [43]. Specifically, STAT3 stimulates SOCS3 gene transcription and the resulting protein binds phospho-JAKs and/or the receptors to turn off the cascade.

Other than SOCS, STAT3 transcriptional activity is controlled by PIAS3, a nuclear protein member of PIAS family proteins which prevents active STAT3 from binding DNA and inhibits STAT3-mediated gene activation [44].

Furthermore, STAT3 transcriptional activity is controlled by PTPs, a family of tyrosine phosphatases, that operate on various steps of signaling cascade. The best characterization of these proteins is SHP-1 and SHP-2 that contain SH2 domain and ensure that tyrosine phosphorylation of JAKs does not persist after the removal of the cytokine [2, 12]. Inactivation of STAT3 in the nucleus occurs through the dephosphorylation of Tyr705 by TC-PTP and TC45 [45].

There is a growing body of evidence demonstrating that STAT3 signaling is also regulated via a complex interplay with cellular miRNAs. Both direct and indirect regulatory mechanisms mediate several positive and negative feedback loops between miRNAs and the STAT3 signaling pathway. Approximately, 50 miRNAs are predicted to bind the 3'-UTR of STAT3; among them, let-7, miR-20a, and miR-93 were directly validated using STAT3-3'-UTR-Reporter constructs. Several miRNAs directly induce STAT3 upregulation (miR-551b 3p) or act to reduce the expression of negative regulators of STAT3 (miR-18a, miR-221, and miR-222), and others are activated by STAT3 (miR-21) through binding within the promoters of these oncomiRs. A more thorough review can be found in the manuscript by [46].

2.3. STAT3 and Oncogenesis. Growing evidence over the last years suggests a critical role of STAT3 as a point of convergence of various signaling pathways that are deregulated in cancer. In healthy cells, STAT3 is closely regulated to maintain a transient active state. Conversely, STAT3 is improperly and persistently activated in numerous hematopoietic and solid malignancies [47, 48]. Constitutively active STAT3 induces deregulation of growth and survival, promotion of angiogenesis, and suppression of host's immune surveillance against tumor. Moreover, it promotes epithelial-mesenchymal transition, invasion, and metastasis thereby contributing to tumor progression. In the last years, increasing evidence indicates that STAT3 also promotes resistance to conventional chemo- and radiation therapy as well as to pharmacological inhibition of several pathways of oncogene-driven malignancies [49, 50].

Although recent studies have revealed activating STAT3 mutations in some malignancies (hepatocellular adenoma, 40% of large granular lymphocytic leukemia, and 30% of chronic lymphoproliferative disease of NK cells), these mutations are too rare to account for the high prevalence of STAT3 activation in solid tumors.

The constitutive activation of STAT3 in cancer is caused mostly by the higher secretion of cytokines and growth factors in tumor microenvironment. Furthermore, in this




FIGURE 2: Strategies for inhibition of the STAT3 signaling pathway. Several agents targeting various nodes of STAT3 cascade have been developed. Agents that act on nodes 1 and 2 indirectly switch off STAT3 signaling. Compounds at node 3 directly target STAT3 protein or its DNA-binding downmodulating STAT3 activation. p-STAT3: phosphorylated STAT3; p-JAKs: phosphorylated JAKs.

context, it has been recognized a critical role to the deregulation of receptors with intrinsic tyrosine kinase activity (e.g., EGFR or HER-2/neu) or of nonreceptor tyrosine kinases (e.g., Src or Abl), as well as to the epigenetic modulation of negative regulators of STAT3. High levels of IL-6 have been reported in a lot of cancer patients and are also described as a potent negative regulator of dendritic cell maturation *in vivo*, contributing to control T cell-mediated immune responses [51].

Studies of myeloma, hepatocellular carcinomas, and non-small-cell lung cancer report the loss of proteins that negatively regulate STAT3, such as PIAS [52] or SOCS [53].

On the other hand, JAK mutations and their relevance in the pathogenesis of hematological disorders are well described, with JAK2 V617F being the most well-known mutation, which is found in >95% of patients with polycythemia vera, primary myelofibrosis, and essential thrombocytosis [54]. Mutations in the genes encoding JAK enzymes seem to be much less common in solid tumors.

Abnormal STAT3 signaling is also associated with defects in activation of JAKs due to a chromosomal translocation resulting in a fusion protein that contains the kinase domain of JAK2 fused to the oligomerization domain of the Ets transcription factor (Tel-JAK2) and possesses constitutive tyrosine kinase activity [55].

It has been reported that also noncanonical pathways of STAT3 signaling play a significant role in malignant transformation, causing alternative posttranslational modifications like phosphorylation of Ser727 and acetylation of Lys685 [56–59].

In the last years, miRNAs are emerging as important regulators of the JAK-STAT3 pathway in the pathogenesis of cancer, causing up- or downmodulation of STAT3 signaling, as well as in the development of chemoresistance in several types of cancer. Further insights on the subject are by [46].

2.4. Treatment Strategies Targeting STAT3 Protein. The understanding that STAT3 signaling promotes tumorigenesis and chemoresistance while severely hinders antitumor immunity has stimulated the search for clinical agents that can effectively inhibit this pathway. Over the last 15 years, many direct or indirect inhibitors targeting various members of the STAT3 pathway have been employed to disrupt STAT3 activity (Figure 2) and some of them entered in clinical trials for treatment of solid or hematological tumor.

Two principal approaches that indirectly inhibit STAT3 activation have been developed. First of all, antibodies that target IL-6 or its receptor are extensively evaluated preclinically and clinically (Figure 2, node 1). Siltuximab and tocilizumab are two antibodies approved by the FDA for the treatment of arthritis or Castleman disease that have been testing in phase I/II clinical trials in different hematological as well as solid tumor [60–65]. Another indirect but efficient mechanism is the use of JAK or Src inhibitors (Figure 2, node 2) [66]. A number of small JAK and Src inhibitors are now in various stages of clinical trials, and some of them result in approved drugs, specifically ruxolitinib and tofacitinib [67]. Other JAK and Src inhibitors such as AZD1480, WP-1066, dasatinib, and saracatinib demonstrate the reduction of STAT3 phosphorylation as well as

downstream implications like increased apoptosis and decreased tumor growth [68–71]. Unfortunately, the JAK and IL-6 inhibitors determine an increased rate of infection and off-target neurotoxicity. Moreover, the inhibition of these kinases may influence different signaling cascades and give rise to additional off-target effects. For example, the crucial role of STAT1 in inflammatory response and in disrupting cell proliferation is well known, as well as in antitumor and immune surveillance [72–75]. Therefore, STAT1 should not be downregulated, while attempting to inhibit the actions of STAT3. It is clear that further investigation of all these inhibitors is necessary to understand how to optimize STAT3 inhibition.

For all these reasons, a better strategy for STAT3 inhibition is through the direct targeting of functional phosphorylated STAT3. A lot of peptides and small molecules that impair dimerization, nuclear translocation, and DNA binding of STAT3 have been developed (Figure 2, node 3).

The small peptides designed on STAT3 SH2 domain sequence that contain a tyrosine-phosphorylation site (PY*LTKK) bind to the SH2 domain of STAT3 preventing its dimerization and translocation into the nucleus [76, 77]. Although these compounds have proapoptotic and antitumor activity in cancer cells, they have primarily been used as research tools due to their limited cellular uptake and stability.

Nonpeptidic small molecules able to permeate cells represent a more attractive approach to inhibit aberrant STAT3 activity in cancer cells [78]. Compounds, such as STATTIC, STA-21, LLL-3, LLL-12, WP1066, S3I-201, BP-1-102, STX-0119, and HJC0123, inhibit the growth of tumor cells with hyperactivated STAT3 [79–82]. Although many SH2 domain inhibitors have proved to be promising in laboratory studies, only a few have been evaluated in clinical trials.

An alternative approach useful to inhibit STAT3 function involves competitive inhibition of the interactions between DBD domain of STAT3 and promoter elements in target genes. Platinum (IV) complex, such as CPA-1, CPA-7, and IS3-295, inhibits the STAT3 DNA-binding activity leading to apoptosis in human cancer cell lines [83]. A 15 bp double-stranded decoy oligonucleotide that correspond to the STAT3 response element in the *cFOS* promoter competitively inhibits STAT3 DNA binding and suppresses the tumor growth of preclinical models of ovarian, breast, head-and-neck, lung, brain, and skin cancers as well as acute myeloid leukemia [84–87].

Although many of these anti-STAT3 compounds have antitumor effects *in vitro* and *in vivo*, there are no currently approved drug directly targeting STAT3 and the research of STAT3 inhibitors is still evolving.

3. Redox Homeostasis in Cancer Cells

3.1. Intracellular Redox Homeostasis. In contrast to normal tissue, most of solid tumors are characterized by regions of low oxygen (hypoxia), low pH, and low levels of glucose which result from an architecturally abnormal microcircula-

tion, rapid growth of tumor cells, and high interstitial pressure. Hypoxia and the high energetic metabolism induced by tumor microenvironment contribute to upregulation of reactive oxygen species (ROS) production in mitochondria, peroxisomes, and endoplasmic reticulum [88–91]. Excessive levels of ROS cause oxidative damage to DNA, proteins, and lipids, compromising their structures and function. To prevent oxidative damage, cancer cells activate various enzymatic and nonenzymatic antioxidant systems. The first ones include superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase whereas α -tocopherol (vitamin E), β -carotene (vitamin A), ascorbic acid (vitamin C), and uric acid represent the ROS scavenging molecules. Furthermore, multiple and interrelated redox couples, such as NADPH/NADP⁺, GSH/GSSG, Trx/TrxSS, and cysteine/cystine, contribute to the intracellular redox homeostasis [92–99].

A number of human cancer tissues, including breast, brain, colon, pancreas, lungs, and leukemia, produce high concentrations of glutathione (GSH) that contribute to cancer initiation, progression, and metastasis formation and to chemoresistance [100–103]. In accordance with the elevated level of GSH in cancer cells, several drugs known to reduce GSH concentration are currently being used in clinical trials to improve efficacy of targeted therapy. In this regard, the use of disulfiram, alone or combined with arsenic trioxide, has been approved as therapy for metastatic melanoma and non-acute promyelocytic leukemia [101, 104]. Buthionine sulfoximine (BSO), a synthetic inhibitor of GSH production, confers increased sensitivity to chemotherapy in myeloma and neck cancers [105] and has been clinically used in various types of cancers [106]. Similarly, phenylethyl isothiocyanate (PEITC), which conjugates with GSH, inhibits the oncogenic transformation of ovarian epithelial cells and hematopoietic cells [107].

Collectively, modulation of the GSH level is an alternative way to increase the sensitivity of tumor cells to conventional chemotherapy and provides a viable option for patients suffering from therapy-resistant tumors.

3.2. [GSH]/[GSSG] Redox Couple. The tripeptide glutathione (Glu-Gly-Cys) is the most abundant intracellular nonenzymatic ROS scavenger reaching millimolar concentrations in the cells. Intracellular glutathione can exist as a monomer in its reduced form (GSH) or as a disulfide dimer (GSSG) after its oxidation which usually accounts for less than 1% of the total intracellular glutathione content.

As antioxidant and intracellular redox buffer, GSH has essential roles in ROS scavenging and in detoxification of electrophiles, xenobiotics, and heavy metals. Two oxidized GSH molecules dimerize by a SS bond to form GSSG. Glutathione reductase, a NADPH-dependent enzyme, reverts this reaction to reconstitute GSH pool. GSH reduces peroxides and generates GSSG via glutathione peroxidase (GPx) or it reacts with many electrophiles to generate glutathione S-conjugates (GS-R). Although these reactions can occur spontaneously, they are often catalyzed by the glutathione S-transferase (GST) [108, 109] (Figure 3).




FIGURE 3: Antioxidant function of glutathione. GST: glutathione transferase; GS-R: electrophile-GSH adduct; GPx: glutathione peroxidase; GR: glutathione reductase.

The cellular redox status can be evaluated measuring the GSH/GSSG ratio by the Nernst equation [110]. At 25°C and pH 7, E° of the GSH/GSSG redox couple is



Since two GSH molecules are needed to form one GSSG molecule, the reaction is second order with respect to GSH. Thus, any changes in the absolute concentration of GSH will change the redox potential, even without changes in the GSH/GSSG ratio. This suggests that cells with much higher GSH level have a greater reducing capacity than cells with lower GSH concentration.

The cellular redox state is one of the master regulators of different cellular processes, and physiological cellular function is maintained by a fine balance between reducing and oxidizing conditions. It has been reported that the etiology and/or progression of many human diseases, including cancer, are related to GSH/GSSG homeostasis. Generally, elevated levels of GSH that determine a more reducing cellular environment stimulate cell proliferation whereas a mild oxidizing environment results in cell differentiation. A further shift toward a more oxidant cellular environment leads to apoptosis or necrosis [108, 110, 111].

3.3. Redox Regulation of STAT3. Under oxidative stress, many proteins undergo reversible and irreversible oxidative modifications, which may lead to changes in the structure and/or function of the oxidized protein. These redox-sensitive proteins exhibit a striking differential susceptibility to oxidative stress; while a protein may contain numerous residues, only a minority of them will have the chemical properties to function as a possible target site for oxidant. This is largely due to the reactivity of anionic sulfur of various oxidizing agents.

Mild oxidative stress induces selective modifications of proteins at critical cysteine thiols including reversible oxidation to sulfenic acids, intra- and intermolecular disulfides, S-glutathionylation, and S-nitrosylation [112]. S-Glutathionylation, the reversible formation of protein-mixed disulfides with GSH, represents the most common steady-state derivative due to cellular abundance of GSH and ready conversion

of cysteine-sulfenic acid and S-nitrosocysteine precursors to S-glutathionylcysteine disulfides. This reaction may protect proteins from irreversible damage or modulate protein function. Conversely, excessive oxidative stress is associated with permanent loss of function, misfolding, and aggregation due to irreversible modification of SH groups of protein [113–115].

Several studies demonstrate that intracellular redox environment influences STAT3 activation cascade although it is still not clear if ROS up- or down-regulate STAT3 activation. Some authors report that ROS trigger Tyr705 STAT3 phosphorylation and upregulate its DNA-binding activity [116, 117]. On the other hand, other authors indicate that ROS oxidize conserved cysteines in STAT3 DNA-binding domain impairing its transcriptional activity [118, 119]. Moreover, there is evidence from the literature which prove that ROS scavengers and inhibitors of NADPH oxidase enzymes (NOX) generally inhibit STAT3 activity [120, 121]. In addition, it has been shown that nitrosocyclohexyl acetate, a nitroxyl donor, inhibits STAT3 phosphorylation through the formation of sulfenic acid at the cysteine residues in endothelial cells [122].

S-Glutathionylation and S-nitrosylation inhibit STAT3 phosphorylation as well as its DNA-binding activity in different cell lines and in *in vitro* studies. Although the 3D model of nitrosylated/glutathionylated STAT3 is not available, it can be speculated that the small conformational changes induced by NO or GSH addition could in turn induce a conformational change in the phosphorylation site of protein inhibiting accessibility to JAKs [119, 123–125].

Our group has been studying STAT3 redox regulation for the past ten years. Particularly, we identified three sesquiterpene lactones, costunolide, dehydrocostuslactone, and cynaropicrin, able to inhibit IL-6-induced as well as constitutive activation of STAT3 in different cancer cell lines. These compounds disrupt intracellular redox homeostasis, induce reversible S-glutathionylation of STAT3, and decrease its Tyr705 phosphorylation [126, 127]. Deepening inside the redox regulation of STAT3 signaling, we reported that Cys328 and Cys542 in the DNA-binding domain and in the linker domain, respectively, are a target of S-glutathionylation [123, 128].

Since STAT3 is validated as a therapeutic target in different solid and hematologic tumor, the modulation of oxidative stress could be a new strategy to inhibit STAT3 hyperactivation. On the other end, the consequent decrease in GSH levels could sensitize tumor cells to conventional chemotherapy.

4. Sesquiterpene Lactones

4.1. Sesquiterpene Lactone Structure. Sesquiterpene lactones (SLs) are colorless, bitter, and stable compounds of terpenoids, a class of lipophilic plant secondary metabolites. More than 5000 SLs have been characterized in species of the plant kingdom, in particular in the family Asteraceae, and plant extracts rich in SLs have long been employed in traditional medicine against inflammatory-related diseases. SLs possess a broad spectrum of biological activities, including anti-inflammatory, antibacterial, and immunomodulatory effects. These compounds also inhibit cell cycle and proliferation and




FIGURE 4: (a) Chemical structure of SLs that induce STAT3 S-glutathionylation and impair STAT3 phosphorylation. The reactive centre of SLs is evidenced with a red circle. (b) Schematic representation of Michael reaction.

induce apoptosis, in different cancer cell lines and in many *in vivo* studies [129–131]. Although the exact mechanisms of action are not well elucidated, emerging data suggest that the biological effect of SLs is associated with depletion of GSH and ROS generation [126, 127, 132, 133].

SLs are 15 carbon compounds consisting of three isoprene (5-C) units arranged in several characteristic ring systems, including one or more lactone rings. The α,β -unsaturated carbonyl group present in most of these compounds is the major responsible for their biological effects [134]. The α,β -unsaturated carbonyl group is a strong alkylating agent that may react by Michael-type addition with intracellular nucleophiles, such as cysteine sulfhydryl

residues in proteins, leading to disruption of their biological function. The α,β -unsaturated carbonyl moiety may also react with the sulfhydryl group of cysteine residue in GSH leading to redox homeostasis disruption and oxidative stress in cells (Figure 4(b)) [134–136].

Further chemical features, such as lipophilicity and molecular geometry of compounds as well as the chemical environment of the target nucleophiles, also influence the bioavailability and biological activity of SLs [137, 138].

4.2. Sesquiterpene Lactones and STAT3. In the last years, many natural SLs able to induce apoptosis through the inhibition of STAT3 signaling have been recognized in

TABLE 2: Anti-STAT3 SLs.

Compound	Cell lines/murine model	STAT3 signaling	Molecular mechanism of STAT3 inhibition	Oxidative stress	Biological effect
Alantolactone	A549, NCI-H1650 [139]	p ^{Tyr705} STAT3 STAT3 DNA binding ↓	STAT3 glutathionylation ↓	ROS ↑ GSH/GSSG ↓	Apoptosis ↑ Enhanced chemosensitivity ↓
	HepG2 [140]	p ^{Tyr705} STAT3 ↓	STAT3 glutathionylation? ↓	ROS [GSH] ↑ ↓	Apoptosis ↑ ↓
	MDA-MB231, MCF-7 [141]	p ^{Tyr705} STAT3 ↓	STAT3 glutathionylation? ↓	ROS [GSH] ↑ ↓	Apoptosis ↑ ↓
Santamarine	BxPC-3, AsPC-1, PANC-1 Athymic BALB/cA [142]	p ^{Tyr705} STAT3 ↓	Binding to STAT3 SH2 domain ↓	No evaluated	Inhibited cell migration Enhanced chemosensitivity
	HepG2 [143]	p ^{Tyr705} STAT3 ↓ pSrc ↓	STAT3 glutathionylation? ↓	ROS ↑ GSH/GSSG ↓	Apoptosis ↑ ↓
Parthenolide	SGC-7901/DDP [144]	p ^{Tyr705} STAT3 ↓	?	No evaluated	Apoptosis ↑ Inhibited cell migration and invasion Enhanced chemosensitivity
	HepG2, HT-29, Lovo, MDA-MB-231, MDA-MB-468, HCT116, H460, NCI-H1299, Colo205, BGC [145]	p ^{Tyr705} STAT3 ↓ p ^{Tyr1007/1008} JAK2 ↓	Binding to JAK2 ↓	ROS ↑	Cytotoxicity ↑
Costunolide	THP1 [126]	p ^{Tyr705} STAT3 ↓ p ^{Tyr1007/1008} JAK2 ↓ p ^{Tyr1022/1023} JAK1 ↓ p ^{Tyr1054/1055} TyK2 ↓	STAT3 glutathionylation? ↓	ROS ↑ GSH/GSSG ↓	
	SK-Hep-1, HepG2, SMMC-7721 [146]	p ^{Tyr705} STAT3 ↓ p ^{Tyr1007/1008} JAK2 ↓	STAT3 glutathionylation? ↓	ROS ↑ GSH/GSSG ↓	Cytostatic ↑ Apoptosis ↓
Bigelovin	HCT 116 HT-29 26-M01 BALB/c nude mice [147, 148]	p ^{Tyr705} STAT3 ↓ STAT3 ↓	STAT3 glutathionylation? ↓	ROS ↑	Inhibited cell migration and invasion ↑ Apoptosis ↓
	THP1 [126]	p ^{Tyr705} STAT3 ↓ p ^{Tyr1007/1008} JAK2 ↓ p ^{Tyr1022/1023} JAK1 ↓ p ^{Tyr1054/1055} TyK2 ↓	STAT3 glutathionylation? ↓	ROS ↑ GSH/GSSG ↓	
Dehydrocostuslactone	MCF-7, MDA-MB-231 BALB/cA-nu [149]	p ^{Tyr1007/1008} JAK2 ↓ p ^{Tyr1022/1023} JAK1 ↓ p ^{Tyr705} STAT3 ↓	SOCS-1 ↑ SOCS-3 ↓	No evaluated	Cell cycle arrest ↑ Apoptosis ↓
	K562 [150]	p ^{Tyr1007/1008} JAK2 ↓ p ^{Tyr705} STAT3 ↓	?	ROS ↑	Apoptosis ↑

TABLE 2: Continued.

Compound	Cell lines/murine model	STAT3 signaling	Molecular mechanism of STAT3 inhibition	Oxidative stress	Biological effect
Cynaropicrin	THP-1 DU-145 [127]	p ^{Tyr705} STAT3 STAT3 DNA binding ↓	STAT3 glutathionylation? ↓	ROS [GSH] ↓	Apoptosis Enhanced chemosensitivity
Deoxyelephantopin	HCT 116, K562, KB, T47D [151] B16-F10, MeWo A375, A2058, SK-MEL-2 NOD/SCID mice [152]	p ^{Tyr705} STAT3 p ^{Tyr705} STAT3 ↓	STAT3 glutathionylation? ↓	ROS ROS ↑	Cytotoxicity Apoptosis Autophagy Cytotoxicity Apoptosis Enhanced chemosensitivity
6-O-angeloylplenolin	NCI-H1975, L78, NCI-292, HCC827, A549, 16HBE, BEAS-2B SCID mice [153]	p ^{Tyr705} STAT3 ↓	Binding to STAT3 SH2 domain ↓	Not evaluated	Apoptosis
	MM.1S, MM.1R, U266 BALB/c nude mice [154]	p ^{Tyr705} STAT3 p ^{Tyr1007/1008} JAK2 ↓	? ↓	Not evaluated	Apoptosis Enhanced chemosensitivity
Antrocin	A549, H1975, H441, PC9, BEAS-2B Mice [155]	p ^{Tyr705} STAT3 p ^{Tyr1007/1008} JAK2 p ^{Tyr1022/1023} JAK1 p ^{Tyr1054/1055} Tyk2 STAT3 DNA binding ↓	? ↓		Apoptosis




FIGURE 5: Cancer cells are characterized by elevated levels of GSH that confer resistance to several chemotherapeutic drugs and by constitutive activation of STAT3 signaling that contributes to tumorigenesis and tumor growth, promotes angiogenesis and metastasis, suppresses immune response, and induces chemoresistance (red line). SLs inhibit STAT3 signaling targeting different steps in the signaling cascade (black line). The mild oxidative stress, derived by the direct binding of SLs to GSH, induced S-glutathionylation of STAT3 switching off STAT3 signaling (black line). Moreover, the reduced GSH levels contribute to overcome chemoresistance. GST: glutathione transferase; GS-R: drug-GSH adduct; GSS-STAT3: glutathionylated STAT3; p-STAT3: phosphorylated STAT3; pJAKs: phosphorylated JAKs.

different cancer cellular and animal models (Table 2) [126, 127, 139–155]. Induction of apoptosis was found to be linked with increased ROS production, GSH depletion, and modulation of GSH/GSSG ratio. Although the final biological outcome of all SLs is well described, the molecular mechanism of anti-STAT3 activity is not reported for all of them. Cheng et al. demonstrate that 6-O-angeloylplenolin directly interacts with the SH2 domain of STAT3 and inhibits the constitutive and IL-6-induced STAT3 activity in lung cancer cells [153]. A direct interaction with STAT3 SH2 domain is also reported for alantolactone [142]. Furthermore, Liu et al. describe that parthenolide covalently binds to Cys residues of JAKs suppressing its kinase activity and downmodulating the STAT3 pathway [145].

Other studies show that SLs inhibit STAT3 signaling through S-glutathionylation of Cys residues in STAT3 protein. Dehydrocostuslactone, costunolide, cynaropicrin, and alantolactone that contain an α - β -unsaturated carbonyl group directly interact with GSH by Michael addition and induce a rapid drop in GSH concentration, thereby triggering S-glutathionylation of STAT3. This event impairs STAT3 phosphorylation switching off the signaling cascade (Figure 4(b)) [126, 127, 139]. It is possible to speculate that S-glutathionylation is the common molecular mechanism of anti-STAT3 activity of other SLs able to disrupt GSH/GSSG homeostasis [140, 141, 143, 146–148, 150–152]. The exact molecular mechanism by which S-glutathionylation inhibits STAT3 phosphorylation is not completely clarified. We

reported that S-glutathionylation of STAT3 slightly modulates the secondary and tertiary structure of STAT3 affecting the phosphorylation site thus hampering the recognition of Tyr705 site by JAKs [123].

Various *in vitro* and *in vivo* studies reveal that suppression of STAT3 activation by SLs overcomes drug resistance [127, 139, 142, 144, 152, 154, 155]. Since the central role of STAT3 in carcinogenesis and chemoresistance, SLs able to switch off STAT3 signaling have gained considerable attention from the researchers for the development of a new therapeutic strategy for cancer treatment.

5. Concluding Remarks

Very often, the rational development of drugs that kill cancer cells interacting with one signaling has a sporadic success due to the activation of other pathways as well as to the development of chemoresistance. It is known that oxidative stress is closely related to carcinogenesis and to resistance toward classical drug treatment. Therefore, the use of molecules able to reduce STAT3 activation and, on the other hand, to induce a mild oxidative stress in a high-reduced cellular environment may potentially improve cancer treatment outcome. In this context, SLs are promising compounds in cancer drug discovery and their anti-STAT3 activity as well as their ability to disrupt redox homeostasis place them as lead compounds in the development of innovative therapies (Figure 5).

Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgments

The authors' research was supported by the Joint Project 2017 (University of Verona, Italy, and Aboca, Sansepolcro (AR) Italy) and by funds from the Italian Ministry for Research and Education (FUR2018MS).

References

- [1] Y. Nagata and K. Todokoro, "Interleukin 3 activates not only JAK2 and STAT5, but also Tyk2, STAT1, and STAT3," *Biochemical and Biophysical Research Communications*, vol. 221, no. 3, pp. 785–789, 1996.
- [2] P. C. Heinrich, I. Behrmann, G. Müller-Newen, F. Schaper, and L. Graeve, "Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway," *Biochemical Journal*, vol. 334, no. 2, pp. 297–314, 1998.
- [3] E. Caldenhoven, T. B. van Dijk, R. Solari et al., "STAT3 β , a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription," *Journal of Biological Chemistry*, vol. 271, no. 22, pp. 13221–13227, 1996.
- [4] S. Becker, G. L. Corthals, R. Aebersold, B. Groner, and C. W. Müller, "Expression of a tyrosine phosphorylated, DNA binding Stat3 β dimer in bacteria," *FEBS Letters*, vol. 441, no. 1, pp. 141–147, 1998.
- [5] Z. Ren, X. Mao, C. Mertens et al., "Crystal structure of unphosphorylated STAT3 core fragment," *Biochemical and Biophysical Research Communications*, vol. 374, no. 1, pp. 1–5, 2008.
- [6] X. Zhang and J. E. Darnell Jr., "Functional importance of Stat3 tetramerization in activation of the α 2-macroglobulin gene," *Journal of Biological Chemistry*, vol. 276, no. 36, pp. 33576–33581, 2001.
- [7] J. X. Lin, P. Li, D. Liu et al., "Critical role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function," *Immunity*, vol. 36, no. 4, pp. 586–599, 2012.
- [8] J. Ma, T. Zhang, V. Novotny-Diermayr, A. L. C. Tan, and X. Cao, "A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation," *Journal of Biological Chemistry*, vol. 278, no. 31, pp. 29252–29260, 2003.
- [9] J. Yang, J. Huang, M. Dasgupta et al., "Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 50, pp. 21499–21504, 2010.
- [10] S. Haan, U. Hemmann, U. Hassiepen et al., "Characterization and binding specificity of the monomeric STAT3-SH2 domain," *Journal of Biological Chemistry*, vol. 274, no. 3, pp. 1342–1348, 1999.
- [11] E. Butturini, G. Gotte, D. Dell'Orco et al., "Intermolecular disulfide bond influences unphosphorylated STAT3 dimerization and function," *Biochemical Journal*, vol. 473, no. 19, pp. 3205–3219, 2016.
- [12] M. Benekli, H. Baumann, and M. Wetzler, "Targeting signal transducer and activator of transcription signaling pathway in leukemias," *Journal of Clinical Oncology*, vol. 27, no. 26, pp. 4422–4432, 2009.
- [13] J. E. Darnell Jr., "STATs and gene regulation," *Science*, vol. 277, no. 5332, pp. 1630–1635, 1997.
- [14] Z. Zhong, Z. Wen, and J. Darnell, "Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6," *Science*, vol. 264, no. 5155, pp. 95–98, 1994.
- [15] C. Yu, D. Meyer, G. Campbell et al., "Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein," *Science*, vol. 269, no. 5220, pp. 81–83, 1995.
- [16] J. Turkson, T. Bowman, R. Garcia, E. Caldenhoven, R. P. de Groot, and R. Jove, "Stat3 activation by Src induces specific gene regulation and is required for cell transformation," *Molecular and Cellular Biology*, vol. 18, no. 5, pp. 2545–2552, 1998.
- [17] J. F. Bromberg, C. M. Horvath, D. Besser, W. W. Lathem, and J. E. Darnell Jr., "Stat3 activation is required for cellular transformation by v-src," *Molecular and Cellular Biology*, vol. 18, no. 5, pp. 2553–2558, 1998.
- [18] Z. Wen, Z. Zhong, and J. E. Darnell Jr., "Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation," *Cell*, vol. 82, no. 2, pp. 241–250, 1995.
- [19] Z. Wen and Darnell JE Jr., "Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3," *Nucleic Acids Research*, vol. 25, no. 11, pp. 2062–2067, 1997.
- [20] C. P. Lim and X. Cao, "Serine phosphorylation and negative regulation of Stat3 by JNK," *Journal of Biological Chemistry*, vol. 274, no. 43, pp. 31055–31061, 1999.
- [21] H. Yu, D. Pardoll, and R. Jove, "STATs in cancer inflammation and immunity: a leading role for STAT3," *Nature Reviews Cancer*, vol. 9, no. 11, pp. 798–809, 2009.
- [22] R. Catlett-Falcone, T. H. Landowski, M. M. Oshiro et al., "Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells," *Immunity*, vol. 10, no. 1, pp. 105–115, 1999.
- [23] W. Li, M. R. Lee, T. Kim, Y. W. Kim, and M. Y. Cho, "Activated STAT3 may participate in tumor progression through increasing CD133/survivin expression in early stage of colon cancer," *Biochemical and Biophysical Research Communications*, vol. 497, no. 1, pp. 354–361, 2018.
- [24] H. Huang, W. Zhao, and D. Yang, "Stat3 induces oncogenic Skp2 expression in human cervical carcinoma cells," *Biochemical and Biophysical Research Communications*, vol. 418, no. 1, pp. 186–190, 2012.
- [25] H. Y. Lin, S. C. Hou, S. C. Chen et al., "(–)-epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells," *Journal of Agricultural and Food Chemistry*, vol. 60, no. 10, pp. 2480–2489, 2012.
- [26] K. Liu, H. Gao, Q. Wang et al., "Hispidulin suppresses cell growth and metastasis by targeting PIMI through JAK2/STAT3 signaling in colorectal cancer," *Cancer Science*, vol. 109, no. 5, pp. 1369–1381, 2018.
- [27] F. C. Hsieh, G. Cheng, and J. Lin, "Evaluation of potential Stat3-regulated genes in human breast cancer," *Biochemical and Biophysical Research Communications*, vol. 335, no. 2, pp. 292–299, 2005.

- [28] G. Zhao, G. Zhu, Y. Huang et al., "IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C promoting growth, invasion and lymphangiogenesis in gastric cancer," *Oncology Reports*, vol. 35, no. 3, pp. 1787–1795, 2016.
- [29] M. Zhao, F. H. Gao, J. Y. Wang et al., "JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer," *Lung Cancer*, vol. 73, no. 3, pp. 366–374, 2011.
- [30] M. Kortylewski, H. Xin, M. Kujawski et al., "Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment," *Cancer Cell*, vol. 15, no. 2, pp. 114–123, 2009.
- [31] X. Xuan, S. Li, X. Lou et al., "Stat3 promotes invasion of esophageal squamous cell carcinoma through up-regulation of MMP2," *Molecular Biology Reports*, vol. 42, no. 5, pp. 907–915, 2015.
- [32] S. A. Tsareva, R. Moriggl, F. M. Corvinus et al., "Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metal loproteinase induction," *Neoplasia*, vol. 9, no. 4, pp. 279–291, 2007.
- [33] Z. H. Jia, Y. Jia, F. J. Guo, J. Chen, X. W. Zhang, and M. H. Cui, "Phosphorylation of STAT3 at Tyr705 regulates MMP-9 production in epithelial ovarian cancer," *PLoS One*, vol. 12, no. 8, article e0183622, 2017.
- [34] D. Sun, W. Shen, F. Zhang et al., " α -Hederin inhibits interleukin 6-induced epithelial-to-mesenchymal transition associated with disruption of JAK2/STAT3 signaling in colon cancer cells," *Biomedicine & Pharmacotherapy*, vol. 101, pp. 107–114, 2018.
- [35] Y. Li, M. Bai, Y. Xu, W. Zhao, N. Liu, and J. Yu, "TPPP3 promotes cell proliferation, invasion and tumor metastasis via STAT3/ twist1 pathway in non-small-cell lung carcinoma," *Cellular Physiology and Biochemistry*, vol. 50, no. 5, pp. 2004–2016, 2018.
- [36] T. Wang, J. F. Fahrman, H. Lee et al., "JAK/STAT3-regulated fatty acid β -oxidation is critical for breast cancer stem cell self-renewal and chemoresistance," *Cell Metabolism*, vol. 27, no. 1, pp. 136–150.e5, 2018.
- [37] L. Lin, B. Hutzen, H. F. Lee et al., "Evaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells," *PLoS One*, vol. 8, no. 12, article e82821, 2013.
- [38] L. Hüser, S. Sachindra, K. Granados et al., "SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma," *International Journal of Cancer*, vol. 143, no. 12, pp. 3131–3142, 2018.
- [39] R. Montone, M. G. Romanelli, A. Baruzzi, F. Ferrarini, E. Liboi, and P. M. J. Lievens, "Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLC γ 1/Src-mediated paxillin hyperphosphorylation," *The International Journal of Biochemistry & Cell Biology*, vol. 95, pp. 17–26, 2018.
- [40] Y. Tsujita, A. Horiguchi, S. Tasaki et al., "STAT3 inhibition by WP1066 suppresses the growth and invasiveness of bladder cancer cells," *Oncology Reports*, vol. 38, no. 4, pp. 2197–2204, 2017.
- [41] K. Shuai and B. Liu, "Regulation of JAK-STAT signalling in the immune system," *Nature Reviews Immunology*, vol. 3, no. 11, pp. 900–911, 2003.
- [42] B. B. Aggarwal, A. B. Kunnumakkara, K. B. Harikumar et al., "Signal transducer and activator of transcription-3, inflammation, and cancer," *Annals of the New York Academy of Sciences*, vol. 1171, no. 1, pp. 59–76, 2009.
- [43] E. M. Linossi and S. E. Nicholson, "The SOCS box—adapting proteins for ubiquitination and proteasomal degradation," *IUBMB Life*, vol. 64, no. 4, pp. 316–323, 2012.
- [44] C. D. Chung, J. Liao, B. Liu et al., "Specific inhibition of Stat3 signal transduction by PIAS3," *Science*, vol. 278, no. 5344, pp. 1803–1805, 1997.
- [45] T. Yamamoto, Y. Sekine, K. Kashima et al., "The nuclear isoform of protein-tyrosine phosphatase TC-PTP regulates interleukin-6-mediated signaling pathway through STAT3 dephosphorylation," *Biochemical and Biophysical Research Communications*, vol. 297, no. 4, pp. 811–817, 2002.
- [46] Q. Cao, Y. Y. Li, W. F. He et al., "Interplay between microRNAs and the STAT3 signaling pathway in human cancers," *Physiological Genomics*, vol. 45, no. 24, pp. 1206–1214, 2013.
- [47] J. Turkson and R. Jove, "STAT proteins: novel molecular targets for cancer drug discovery," *Oncogene*, vol. 19, no. 56, pp. 6613–6626, 2000.
- [48] R. Buettner, L. B. Mora, and R. Jove, "Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention," *Clinical Cancer Research*, vol. 8, no. 4, pp. 945–954, 2002.
- [49] A. A. Zulkifli, F. H. Tan, T. L. Putoczki, S. S. Stylli, and R. B. Luwor, "STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics," *Molecular and Cellular Endocrinology*, vol. 451, pp. 15–23, 2017.
- [50] L. Wang, Q. Wang, M. Gao et al., "STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer," *Cancer Science*, vol. 109, no. 10, pp. 3305–3315, 2018.
- [51] S. J. Park, T. Nakagawa, H. Kitamura et al., "IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation," *The Journal of Immunology*, vol. 173, no. 6, pp. 3844–3854, 2004.
- [52] L. Wang and S. Banerjee, "Differential PIAS3 expression in human malignancy," *Oncology Reports*, vol. 11, no. 6, pp. 1319–1324, 2004.
- [53] B. He, L. You, K. Uematsu et al., "SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 24, pp. 14133–14138, 2003.
- [54] C. James, V. Ugo, J. P. le Couédic et al., "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera," *Nature*, vol. 434, no. 7037, pp. 1144–1148, 2005.
- [55] V. Lacronique, A. Boureux, V. D. Valle et al., "A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia," *Science*, vol. 278, no. 5341, pp. 1309–1312, 1997.
- [56] T. Decker and P. Kovarik, "Serine phosphorylation of STATs," *Oncogene*, vol. 19, no. 21, pp. 2628–2637, 2000.
- [57] R. Wang, P. Cherukuri, and J. Luo, "Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation," *Journal of Biological Chemistry*, vol. 280, no. 12, pp. 11528–11534, 2005.
- [58] Z.-l. Yuan, Y.-j. Guan, D. Chatterjee, and Y. E. Chin, "Stat3 dimerization regulated by reversible acetylation of

- a single lysine residue,” *Science*, vol. 307, no. 5707, pp. 269–273, 2005.
- [59] H. J. Kang, Y. W. Yi, S.-J. Hou et al., “Disruption of STAT3-DNMT1 interaction by SH-I-14 induces re-expression of tumor suppressor genes and inhibits growth of triple-negative breast tumor,” *Oncotarget*, vol. 8, no. 48, pp. 83457–83468, 2017.
- [60] K. Suzuki, M. Ogura, Y. Abe et al., “Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma,” *International Journal of Hematology*, vol. 101, no. 3, pp. 286–294, 2015.
- [61] R. Z. Orłowski, L. Gercheva, C. Williams et al., “A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma,” *American Journal of Hematology*, vol. 90, no. 1, pp. 42–49, 2015.
- [62] P. M. Voorhees, R. F. Manges, P. Sonneveld et al., “A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma,” *British Journal of Haematology*, vol. 161, no. 3, pp. 357–366, 2013.
- [63] E. M. Dijkgraaf, S. J. A. M. Santegoets, A. K. L. Reyners et al., “A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon- α 2b in patients with recurrent epithelial ovarian cancer,” *Annals of Oncology*, vol. 26, no. 10, pp. 2141–2149, 2015.
- [64] J. Karkera, H. Steiner, W. Li et al., “The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study,” *The Prostate*, vol. 71, no. 13, pp. 1455–1465, 2011.
- [65] K. Fizazi, J. S. de Bono, A. Flechon et al., “Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer,” *European Journal of Cancer*, vol. 48, no. 1, pp. 85–93, 2012.
- [66] M. Buchert, C. J. Burns, and M. Ernst, “Targeting JAK kinase in solid tumors: emerging opportunities and challenges,” *Oncogene*, vol. 35, no. 8, pp. 939–951, 2016.
- [67] R. K. Rampal, J. O. Mascarenhas, H. E. Kosiorek et al., “Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms,” *Blood Advances*, vol. 2, no. 24, pp. 3572–3580, 2018.
- [68] E. R. Plimack, P. M. LoRusso, P. McCoon et al., “AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors,” *The Oncologist*, vol. 18, no. 7, pp. 819–820, 2013.
- [69] T. Murakami, N. Takigawa, T. Ninomiya et al., “Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model,” *Lung Cancer*, vol. 83, no. 1, pp. 30–36, 2014.
- [70] H. D. Brooks, B. S. Glisson, B. N. Bekele et al., “Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma,” *Cancer*, vol. 117, no. 10, pp. 2112–2119, 2011.
- [71] A. Ferrajoli, S. Faderl, Q. van et al., “WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells,” *Cancer Research*, vol. 67, no. 23, pp. 11291–11299, 2007.
- [72] R. M. Zemek, E. de Jong, W. L. Chin et al., “Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment,” *Science Translational Medicine*, vol. 11, no. 501, article eaav7816, 2019.
- [73] L. Jiang, J. Y. Liu, Y. Shi et al., “MTMR2 promotes invasion and metastasis of gastric cancer via inactivating IFN γ /STAT1 signaling,” *Journal of Experimental & Clinical Cancer Research*, vol. 38, no. 1, p. 206, 2019.
- [74] E. Butturini, D. Boriero, A. Carcereri de Prati, and S. Mariotto, “STAT1 drives M1 microglia activation and neuroinflammation under hypoxia,” *Archives of Biochemistry and Biophysics*, vol. 669, pp. 22–30, 2019.
- [75] A. E. Koromilas and V. Sexl, “The tumor suppressor function of STAT1 in breast cancer,” *JAK-STAT*, vol. 2, no. 2, article e23353, 2013.
- [76] J. Turkson, D. Ryan, J. S. Kim et al., “Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation,” *Journal of Biological Chemistry*, vol. 276, no. 48, pp. 45443–45455, 2001.
- [77] P. K. Mandal, F. Gao, Z. Lu et al., “Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation,” *Journal of Medicinal Chemistry*, vol. 54, no. 10, pp. 3549–3563, 2011.
- [78] S. Fletcher, J. Singh, X. Zhang et al., “Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities,” *ChemBioChem*, vol. 10, no. 12, pp. 1959–1964, 2009.
- [79] J. Schust, B. Sperl, A. Hollis, T. U. Mayer, and T. Berg, “Statistic: a small-molecule inhibitor of STAT3 activation and dimerization,” *Chemistry & Biology*, vol. 13, no. 11, pp. 1235–1242, 2006.
- [80] K. Siddiquee, S. Zhang, W. C. Guida et al., “Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 18, pp. 7391–7396, 2007.
- [81] H. Song, R. Wang, S. Wang, and J. Lin, “A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 13, pp. 4700–4705, 2005.
- [82] B. Fuh, M. Sobo, L. Cen et al., “LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model,” *British Journal of Cancer*, vol. 100, no. 1, pp. 106–112, 2009.
- [83] J. Turkson, S. Zhang, J. Palmer et al., “Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity,” *Molecular Cancer Therapeutics*, vol. 3, no. 12, pp. 1533–1542, 2004.
- [84] P. L. Leong, G. A. Andrews, D. E. Johnson et al., “Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 7, pp. 4138–4143, 2003.
- [85] S. Xi, W. E. Gooding, and J. R. Grandis, “In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy,” *Oncogene*, vol. 24, no. 6, pp. 970–979, 2005.
- [86] J. Shen, R. Li, and G. Li, “Inhibitory effects of decoy-ODN targeting activated STAT3 on human glioma growth in vivo,” *In vivo*, vol. 23, no. 2, pp. 237–243, 2009.

- [87] X. Zhang, J. Zhang, L. Wang, H. Wei, and Z. Tian, "Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice," *BMC Cancer*, vol. 7, no. 1, p. 149, 2007.
- [88] K. Wang, J. Jiang, Y. Lei, S. Zhou, Y. Wei, and C. Huang, "Targeting metabolic-redox circuits for cancer therapy," *Trends in Biochemical Sciences*, vol. 44, no. 5, pp. 401–414, 2019.
- [89] M. Schieber and N. S. Chandel, "ROS function in redox signaling and oxidative stress," *Current Biology*, vol. 24, no. 10, pp. R453–R462, 2014.
- [90] R. A. Cairns, I. S. Harris, and T. W. Mak, "Regulation of cancer cell metabolism," *Nature Reviews Cancer*, vol. 11, no. 2, pp. 85–95, 2011.
- [91] S. S. Sabharwal and P. T. Schumacker, "Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?," *Nature Reviews Cancer*, vol. 14, no. 11, pp. 709–721, 2014.
- [92] W. Xiao, R. S. Wang, D. E. Handy, and J. Loscalzo, "NAD(H) and NADP(H) redox couples and cellular energy metabolism," *Antioxidants & Redox Signaling*, vol. 28, no. 3, pp. 251–272, 2018.
- [93] R. Moreno-Sánchez, J. C. Gallardo-Pérez, S. Rodríguez-Enriquez, E. Saavedra, and Á. Marín-Hernández, "Control of the NADPH supply for oxidative stress handling in cancer cells," *Free Radical Biology & Medicine*, vol. 112, pp. 149–161, 2017.
- [94] H. Jurkowska and M. Wróbel, "Cystathionine promotes the proliferation of human astrocytoma U373 cells," *Anticancer Research*, vol. 38, no. 6, pp. 3501–3505, 2018.
- [95] J. H. Lee, C. Kim, S. G. Lee, G. Sethi, and K. S. Ahn, "Ophiopogonin D, a steroidal glycoside abrogates STAT3 signaling cascade and exhibits anti-cancer activity by causing GSH/GSSG imbalance in lung carcinoma," *Cancers*, vol. 10, no. 11, p. 427, 2018.
- [96] P. Zhang, J. Wu, F. Xiao, D. Zhao, and Y. Luan, "Disulfide bond based polymeric drug carriers for cancer chemotherapy and relevant redox environments in mammals," *Medicinal Research Reviews*, vol. 38, no. 5, pp. 1485–1510, 2018.
- [97] M. L. Circu and T. Y. Aw, "Intestinal redox biology and oxidative stress," *Seminars in Cell & Developmental Biology*, vol. 23, no. 7, pp. 729–737, 2012.
- [98] L. C. Flores, M. G. Roman, G. M. Cunningham et al., "Continuous overexpression of thioredoxin 1 enhances cancer development and does not extend maximum lifespan in male C57BL/6 mice," *Pathobiology of Aging & Age-Related Diseases*, vol. 8, no. 1, article 1533754, 2018.
- [99] B. Haas, L. Schütte, M. Wos-Maganga, S. Weickhardt, M. Timmer, and N. Eckstein, "Thioredoxin confers intrinsic resistance to cytostatic drugs in human glioma cells," *International Journal of Molecular Sciences*, vol. 19, no. 10, p. 2874, 2018.
- [100] A. Bansal and M. C. Simon, "Glutathione metabolism in cancer progression and treatment resistance," *Journal of Cell Biology*, vol. 217, no. 7, pp. 2291–2298, 2018.
- [101] N. Traverso, R. Ricciarelli, M. Nitti et al., "Role of glutathione in cancer progression and chemoresistance," *Oxidative Medicine and Cellular Longevity*, vol. 2013, Article ID 972913, 10 pages, 2013.
- [102] G. Wu, Y. Z. Fang, S. Yang, J. R. Lupton, and N. D. Turner, "Glutathione metabolism and its implications for health," *The Journal of Nutrition*, vol. 134, no. 3, pp. 489–492, 2004.
- [103] S. C. Lu, "Regulation of glutathione synthesis," *Molecular Aspects of Medicine*, vol. 30, no. 1–2, pp. 42–59, 2009.
- [104] C. Conticello, D. Martinetti, L. Adamo et al., "Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies," *International Journal of Cancer*, vol. 131, no. 9, pp. 2197–2203, 2012.
- [105] A. Tagde, H. Singh, M. H. Kang, and C. P. Reynolds, "The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma," *Blood Cancer Journal*, vol. 4, no. 7, article e229, 2014.
- [106] O. W. Griffith, "Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis," *Journal of Biological Chemistry*, vol. 257, pp. 13704–13712, 1982.
- [107] M. Lo, V. Ling, C. Low, Y. Z. Wang, and P. W. Gout, "Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer," *Current Oncology*, vol. 17, no. 3, pp. 9–16, 2010.
- [108] I. Dalle-Donne, A. Milzani, N. Gagliano, R. Colombo, D. Giustarini, and R. Rossi, "Molecular mechanisms and potential clinical significance of S-glutathionylation," *Antioxidants & Redox Signaling*, vol. 10, no. 3, pp. 445–474, 2008.
- [109] A. Pastore, G. Federici, E. Bertini, and F. Piemonte, "Analysis of glutathione: implication in redox and detoxification," *Clinica Chimica Acta*, vol. 333, no. 1, pp. 19–39, 2003.
- [110] F. Q. Schafer and G. R. Buettner, "Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple," *Free Radical Biology & Medicine*, vol. 30, no. 11, pp. 1191–1212, 2001.
- [111] D. P. Jones, "Redox sensing: orthogonal control in cell cycle and apoptosis signalling," *Journal of Internal Medicine*, vol. 268, no. 5, pp. 432–448, 2010.
- [112] J. J. Mieyal, M. M. Gallogly, S. Qanungo, E. A. Sabens, and M. D. Shelton, "Molecular mechanisms and clinical implications of reversible protein S-glutathionylation," *Antioxidants & Redox Signaling*, vol. 10, no. 11, pp. 1941–1988, 2008.
- [113] R. Sitia and S. N. Molteni, "Stress, protein (mis) folding, and signaling: the redox connection," *Science Signaling*, vol. 2004, no. 239, article pe27, 2004.
- [114] J. M. Held and B. W. Gibson, "Regulatory control or oxidative damage? Proteomic approaches to interrogate the role of cysteine oxidation status in biological processes," *Molecular & Cellular Proteomics*, vol. 11, no. 4, 2012.
- [115] C. C. Winterbourn and M. B. Hampton, "Thiol chemistry and specificity in redox signaling," *Free Radical Biology & Medicine*, vol. 45, no. 5, pp. 549–561, 2008.
- [116] M. Carballo, M. Conde, R. el Bekay et al., "Oxidative stress triggers STAT3 tyrosine phosphorylation and nuclear translocation in human lymphocytes," *Journal of Biological Chemistry*, vol. 274, no. 25, pp. 17580–17586, 1999.
- [117] Y. Qu, A. M. Oyan, R. Liu et al., "Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling," *Cancer Research*, vol. 73, no. 23, pp. 7090–7100, 2013.
- [118] L. Li, S. H. Cheung, E. L. Evans, and P. E. Shaw, "Modulation of gene expression and tumor cell growth by redox modification of STAT3," *Cancer Research*, vol. 70, no. 20, pp. 8222–8232, 2010.
- [119] J. I. Kim, S. H. Choi, K. J. Jung, E. Lee, H. Y. Kim, and K. M. Park, "Protective role of methionine sulfoxide reductase A

- against ischemia/reperfusion injury in mouse kidney and its involvement in the regulation of trans-sulfuration pathway," *Antioxidants & Redox Signaling*, vol. 18, no. 17, pp. 2241–2250, 2013.
- [120] A. R. Simon, U. Rai, B. L. Fanburg, and B. H. Cochran, "Activation of the JAK-STAT pathway by reactive oxygen species," *American Journal of Physiology-Cell Physiology*, vol. 275, no. 6, pp. C1640–C1652, 1998.
- [121] G. Waris, K. W. Huh, and A. Siddiqui, "Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF- κ B via oxidative stress," *Molecular and Cellular Biology*, vol. 21, no. 22, pp. 7721–7730, 2001.
- [122] C. Zgheib, M. Kurdi, F. A. Zouein et al., "Acyloxy nitroso compounds inhibit LIF signaling in endothelial cells and cardiac myocytes: evidence that STAT3 signaling is redox-sensitive," *PLoS One*, vol. 7, no. 8, article e43313, 2012.
- [123] E. Butturini, E. Darra, G. Chiavegato et al., "S-Glutathionylation at Cys328 and Cys542 impairs STAT3 phosphorylation," *ACS Chemical Biology*, vol. 9, no. 8, pp. 1885–1893, 2014.
- [124] E. Butturini, F. Cozzolino, D. Boriero et al., "S-Glutathionylation exerts opposing roles in the regulation of STAT1 and STAT3 signaling in reactive microglia," *Free Radical Biology & Medicine*, vol. 117, pp. 191–201, 2018.
- [125] Y. Xie, S. Kole, P. Precht, M. J. Pazin, and M. Bernier, "S-Glutathionylation impairs signal transducer and activator of transcription 3 activation and signaling," *Endocrinology*, vol. 150, no. 3, pp. 1122–1131, 2009.
- [126] E. Butturini, E. Cavalieri, A. Carcereri de Prati et al., "Two naturally occurring terpenes, dehydrocostuslactone and costunolide, decrease intracellular GSH content and inhibit STAT3 activation," *PLoS One*, vol. 6, no. 5, article e20174, 2011.
- [127] E. Butturini, A. Carcereri de Prati, G. Chiavegato et al., "Mild oxidative stress induces S-glutathionylation of STAT3 and enhances chemosensitivity of tumoural cells to chemotherapeutic drugs," *Free Radical Biology & Medicine*, vol. 65, pp. 1322–1330, 2013.
- [128] E. Butturini and D. Boriero, "Carcereri de Prati A., Mariotto S., Immunoprecipitation methods to identify S-glutathionylation in target proteins," *MethodsX*, vol. 6, pp. 1992–1998, 2019.
- [129] J. Y. Cho, K. U. Baik, J. H. Jung, and M. H. Park, "In vitro anti-inflammatory effects of cynaropicrin, a sesquiterpene lactone, from *Saussurea lappa*," *European Journal of Pharmacology*, vol. 398, no. 3, pp. 399–407, 2000.
- [130] A. Bachelier, R. Mayer, and C. D. Klein, "Sesquiterpene lactones are potent and irreversible inhibitors of the antibacterial target enzyme MurA," *Bioorganic & Medicinal Chemistry Letters*, vol. 16, no. 21, pp. 5605–5609, 2006.
- [131] J. Y. Cho, A. R. Kim, H. G. Joo et al., "Cynaropicrin, a sesquiterpene lactone, as a new strong regulator of CD29 and CD98 functions," *Biochemical and Biophysical Research Communications*, vol. 313, no. 4, pp. 954–961, 2004.
- [132] J. Wen, K. R. You, S. Y. Lee, C. H. Song, and D. G. Kim, "Oxidative stress-mediated apoptosis," *Journal of Biological Chemistry*, vol. 277, no. 41, pp. 38954–38964, 2002.
- [133] M. Khan, C. Ding, A. Rasul et al., "Isoalantolactone induces reactive oxygen species mediated apoptosis in pancreatic carcinoma PANC-1 cells," *International Journal of Biological Sciences*, vol. 8, no. 4, pp. 533–547, 2012.
- [134] S. Zhang, Y. K. Won, C. N. Ong, and H. M. Shen, "Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms," *Current Medicinal Chemistry-Anti-Cancer Agents*, vol. 5, no. 3, pp. 239–249, 2005.
- [135] J. Heilmann, M. R. Wasescha, and T. J. Schmidt, "The influence of glutathione and cysteine levels on the cytotoxicity of helenanolide type sesquiterpene lactones against KB cells," *Bioorganic & Medicinal Chemistry*, vol. 9, no. 8, pp. 2189–2194, 2001.
- [136] D. W. Knight, "Feverfew: chemistry and biological activity," *Natural Product Reports*, vol. 12, no. 3, pp. 271–276, 1995.
- [137] A. Ghantous, H. Gali-Muhtasib, H. Vuorela, N. A. Saliba, and N. Darwiche, "What made sesquiterpene lactones reach cancer clinical trials?," *Drug Discovery Today*, vol. 15, no. 15-16, pp. 668–678, 2010.
- [138] M. Chadwick, H. Trewin, F. Gawthrop, and C. Wagstaff, "Sesquiterpenoids lactones: benefits to plants and people," *International Journal of Molecular Sciences*, vol. 14, no. 6, pp. 12780–12805, 2013.
- [139] A. Maryam, T. Mehmood, H. Zhang, Y. Li, M. Khan, and T. Ma, "Alantolactone induces apoptosis, promotes STAT3 glutathionylation and enhances chemosensitivity of A549 lung adenocarcinoma cells to doxorubicin via oxidative stress," *Scientific Reports*, vol. 7, no. 1, p. 6242, 2017.
- [140] M. Khan, T. Li, M. K. Ahmad Khan et al., "Alantolactone induces apoptosis in HepG2 cells through GSH depletion, inhibition of STAT3 activation, and mitochondrial dysfunction," *BioMed Research International*, vol. 2013, Article ID 719858, 11 pages, 2013.
- [141] L. Cui, W. Bu, J. Song et al., "Apoptosis induction by alantolactone in breast cancer MDA-MB-231 cells through reactive oxygen species-mediated mitochondrion-dependent pathway," *Archives of Pharmacal Research*, vol. 41, no. 3, pp. 299–313, 2018.
- [142] H. Zheng, L. Yang, Y. Kang et al., "Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling," *Molecular Carcinogenesis*, vol. 58, no. 4, pp. 565–576, 2019.
- [143] T. Mehmood, A. Maryam, X. Tian, M. Khan, and T. Ma, "Santamarine inhibits NF- κ B and STAT3 activation and induces apoptosis in HepG2 liver cancer cells via oxidative stress," *Journal of Cancer*, vol. 8, no. 18, pp. 3707–3717, 2017.
- [144] H. Li, H. Lu, M. Lv, Q. Wang, and Y. Sun, "Parthenolide facilitates apoptosis and reverses drug-resistance of human gastric carcinoma cells by inhibiting the STAT3 signaling pathway," *Oncology Letters*, vol. 15, no. 3, pp. 3572–3579, 2018.
- [145] M. Liu, C. Xiao, M. Sun, M. Tan, L. Hu, and Q. Yu, "Parthenolide inhibits STAT3 signaling by covalently targeting Janus kinases," *Molecules*, vol. 23, no. 6, p. 1478, 2018.
- [146] X. Y. Fang, H. Zhang, L. Zhao et al., "A new xanthatin analogue 1 β -hydroxyl-5 α -chloro-8-epi-xanthatin induces apoptosis through ROS-mediated ERK/p38 MAPK activation and JAK2/STAT3 inhibition in human hepatocellular carcinoma," *Biochimie*, vol. 152, pp. 43–52, 2018.
- [147] M. Li, L. H. Song, G. G. L. Yue et al., "Bigelovin triggered apoptosis in colorectal cancer in vitro and in vivo via upregulating death receptor 5 and reactive oxidative species," *Scientific Reports*, vol. 7, no. 1, article 42176, 2017.
- [148] M. Li, G. G. L. Yue, L. H. Song et al., "Natural small molecule bigelovin suppresses orthotopic colorectal tumor growth and

- inhibits colorectal cancer metastasis via IL6/STAT3 pathway,” *Biochemical Pharmacology*, vol. 150, pp. 191–201, 2018.
- [149] P. L. Kuo, W. C. Ni, E. M. Tsai, and Y. L. Hsu, “Dehydrocostuslactone disrupts signal transducers and activators of transcription 3 through up-regulation of suppressor of cytokine signaling in breast cancer cells,” *Molecular Cancer Therapeutics*, vol. 8, no. 5, pp. 1328–1339, 2009.
- [150] H. Cai, X. Qin, and C. Yang, “Dehydrocostus lactone suppresses proliferation of human chronic myeloid leukemia cells through Bcr/Abl-JAK/STAT signaling pathways,” *Journal of Cellular Biochemistry*, vol. 118, no. 10, pp. 3381–3390, 2017.
- [151] F. A. Kabeer, D. S. Rajalekshmi, M. S. Nair, and R. Prathapan, “Molecular mechanisms of anticancer activity of deoxyelephantopin in cancer cells,” *Integrative Medicine Research*, vol. 6, no. 2, pp. 190–206, 2017.
- [152] J. H. Feng, K. Nakagawa-Goto, K. H. Lee, and L. F. Shyur, “A novel plant sesquiterpene lactone derivative, DETD-35, suppresses BRAF^{V600E} mutant melanoma growth and overcomes acquired vemurafenib resistance in mice,” *Molecular Cancer Therapeutics*, vol. 15, no. 6, pp. 1163–1176, 2016.
- [153] X. Cheng, Y. Q. Liu, G. Z. Wang et al., “Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor,” *Oncotarget*, vol. 8, no. 2, pp. 2681–2693, 2017.
- [154] Y. Liu, X. Q. Chen, H. X. Liang et al., “Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma,” *PLoS One*, vol. 6, no. 7, article e21930, 2011.
- [155] C. T. Yeh, W. C. Huang, Y. K. Rao et al., “A sesquiterpene lactone antrocin from *Antrodia camphorata* negatively modulates JAK2/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells,” *Carcinogenesis*, vol. 34, no. 12, pp. 2918–2928, 2013.